Our Pipeline

Advancing transformational therapies for rare and life-threatening diseases.

Quetzal Therapeutics is pioneering a new paradigm in the treatment of rare hematologic malignancies and rare diseases.

Our lead candidate, QTX-2101, targets APL with a novel approach to improve outcomes and reduce toxicity.

We are preparing for Phase III clinical trials in late 2025, with registration-enabling activities currently underway.

Leveraging proprietary delivery systems and optimized formulations, we’re expanding our portfolio with additional programs in development—advancing a pipeline built to address unmet clinical needs.

Preclinical

Phase 1

Phase 2

Phase 3

Approved

QTX-2101 – APL → currently moving into Phase III

Phase 3

QTX-2102 – Infectious Disease → Preclinical

Preclinical

Active Pipeline Expansion

In addition to QTX-2101, we are actively pursuing clinical programs with the potential to reshape treatment paradigms across oncology and rare disease spaces.